New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
09:23 EDTGRFS, HALO, CRIS, ING, AMGN, SINA, EXAS, PRAN, MNKD, LULUOn The Fly: Pre-market Movers
HIGHER: Lululemon (LULU), up 3% following upgrade at Wedbush... SINA (SINA), up 3.5% after upgraded at Pacific Crest... Grifols (GRFS), up 2.5% after announcing 7-year agreement with Japanese Red Cross... Exact Sciences (EXAS), up 3.6% after Barron's says shares could rise 50%... Curis (CRIS), up 11% after announcing removal of FDA partial clinical hold on CUDC-427... Halozyme (HALO), up 9% after announcing that trial of Hylenex recombinant met primary endpoint... ING (ING), up 4.5% after paying EUR1.23B to Dutch State... Amgen (AMGN), up 2% after AMG 145 reduced LDL cholesterol in statin intolerant patients... LOWER: Prana (PRAN), down 66% after Alzheimer's study doesn't hit targets... MannKind (MNKD), down 5.6% after downgraded at Piper Jaffray.
News For LULU;MNKD;PRAN;EXAS;SINA;AMGN;ING;CRIS;HALO;GRFS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
12:36 EDTHALOOptions with decreasing implied volatility
Subscribe for More Information
09:04 EDTHALOBaxter, Halozyme launch HYQVIA in U.S.
Subscribe for More Information
08:32 EDTHALOHalozyme receives FDA approval for new Hylenex recombinant facilities
Subscribe for More Information
07:19 EDTAMGNIBC Life Sciences to hold a conference
Subscribe for More Information
06:52 EDTMNKDMannKind initiated with a Neutral at Goldman
Target $6.
October 19, 2014
15:56 EDTAMGNAmgen to aid in production method for Ebola drug ZMapp, Bloomberg says
Subscribe for More Information
October 17, 2014
09:06 EDTAMGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
October 16, 2014
11:21 EDTEXASOptions with decreasing implied volatility: EXAS ATLS LOCO MAT
Subscribe for More Information
10:01 EDTLULUOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Akamai (AKAM) downgraded to Market Perform from Outperform at Wells Fargo... CGG SA (CGG) downgraded to Reduce from Neutral at Nomura... Central Valley Community (CVCY) downgraded to Hold from Buy at Sandler O'Neill... DSM (RDSMY) downgraded to Neutral from Buy at Nomura... Disney (DIS) downgraded at Guggenheim... Francesca's (FRAN) downgraded to Underperform from Outperform at Macquarie... Netflix (NFLX) downgraded to Fair Value from Buy at CRT Capital... Nordstrom (JWN) downgraded to Neutral from Outperform at Macquarie... Norfolk Southern (NSC) downgraded at Credit Suisse... Rio Tinto (RIO) downgraded to Market Perform at Cowen... Seadrill (SDRL) downgraded to Reduce from Neutral at Nomura... Ternium (TX) downgraded to Neutral from Overweight at JPMorgan... Urban Outfitters (URBN) downgraded to Neutral from Outperform at Macquarie... Viacom (VIAB) downgraded at BofA/Merrill... eBay (EBAY) downgraded to Underperform from Buy at CLSA... lululemon (LULU) downgraded to Underperform from Neutral at Macquarie.
07:02 EDTEXASExact Sciences CEO Conroy to be interviewed
CEO Conroy discusses the development of Cologuard, the first and only FDA approved, noninvasive stool DNA screening test for colorectal cancer in an interview on The Traders Network to be held on October 16 at 7:30 am. Webcast Link
06:50 EDTINGEuropean regulator rejects bonus loophole, NY Times says
Subscribe for More Information
05:39 EDTLULUlululemon downgraded to Underperform from Neutral at Macquarie
Macquarie downgraded lululemon to Underperform after assuming coverage of the stock saying the company's expansion into Asia and Europe will drive a meaningful increase in spending. The firm lowered its price target for shares to $34 from $40.
October 15, 2014
11:27 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INO ATLS LOCO OPK INFY EUO FDO
October 14, 2014
11:23 EDTAMGNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:17 EDTEXASOptions with decreasing implied volatility
Subscribe for More Information
October 13, 2014
14:02 EDTLULUlululemon's Q3 sales tracking below consensus, says ITG Research
Subscribe for More Information
12:01 EDTEXASOptions with decreasing implied volatility
Options with decreasing implied volatility: EXAS INFY YUM FDO HSY
11:47 EDTPRANPrana founder claims breakthrough Alzheimer's approach, FierceBiotech says
The scientific founder of Prana Biotechnology, Massachusetts General Hospital investigator Rudy Tanzi, is asserting that he and his fellow researchers have come upon a new approach to growing brain cells in the lab that promises to "revolutionize" Alzheimer's research, reported FierceBiotech. Tanzi is the co-founding scientist and Chief Scientific Adviser at Prana. Reference Link
08:06 EDTSINAQihoo 360 launches ad exchange platform, Marbridge Daily reports
Subscribe for More Information
07:31 EDTEXASExact Sciences price target raised to $42 from $25 at Benchmark Co.
Benchmark Co. raised its price target for Exact Sciences shares to $42 citing the Medicare coverage decision and reimbursement rate of $502 for the company's test. The firm had previously modeled a price of $300 for Cologuard. It reiterates a Buy rating on the name.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use